<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466947</url>
  </required_header>
  <id_info>
    <org_study_id>109563</org_study_id>
    <nct_id>NCT00466947</nct_id>
  </id_info>
  <brief_title>COMPAS (Clinical Otitis Media &amp; Pneumonia Study): Pneumonia &amp; Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine</brief_title>
  <official_title>COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a study in a large number of healthy children less than 3 years old to measure the
      efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate
      vaccine (Synflorix vaccine, or GSK1024850A) to prevent cases of pneumonia (lung infection)
      likely caused by bacteria (Streptococcus pneumoniae and Haemophilus influenzae) or cases of
      otitis media (ear infection) in children under 3 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007. The following vaccines will be offered by the sponsor:

        -  Two doses of hepatitis A vaccine will be offered to all subjects to comply with national
           recommendations.

        -  NeisVac-C vaccine against Neisseria meningitis group C will be offered to all subjects
           in Argentina at 12 months of age.

        -  Varicella vaccine will be offered to all subjects in Colombia and Panama at 12 months of
           age.

        -  Two doses of Rotarix vaccine will be offered to all subjects in Colombia within the
           first six months of life.

      In addition, all subjects will receive a dose of Hepatitis B vaccine at birth according to
      national recommendations and a dose of measles, mumps and rubella (MMR) vaccine at 12 to 15
      months of age according to local Extended Program of Immunization (EPI) .

      These vaccines will not be provided by the sponsor. The protocol posting has been updated
      according to the amendment of the protocol dated 25 Nov 2008. The protocol posting has been
      updated according to the amendment of the protocol dated 14 December 2009. The protocol
      posting has been updated according to the amendment of the protocol dated 09 September 2010.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP)</measure>
    <time_frame>Any time from 2 weeks after Dose 3 up to 31 August 2010</time_frame>
    <description>A B-CAP episode was defined as a radiologically confirmed community acquired pneumoniae (CAP) episode with either alveolar consolidation/pleural effusion on the chest X-ray (CXR) or with non-alveolar infiltrates but with C reactive protein (CRP) higher than or equal to (&gt;=) 40 milligrams per liter (mg/L). The results are presented for data lock point for the primary outcome analysis (31 August 2010), which was performed, as per protocol, when at least 535 first B-CAP episodes were reported from 2 weeks after the third vaccination dose.
After analysis on primary outcome was performed, re-monitoring activities revealed Informed Consent Form issues for some subjects. Therefore, a sensitivity analysis excluding 144 subjects was performed. This analysis confirmed the validity of the results for primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Event (AE), in the Panama Subset</measure>
    <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
    <description>An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. The Panama Subset included all subjects from Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
    <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period following the booster vaccine administration</time_frame>
    <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
    <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset, for the Control Group</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period following the booster vaccine administration.</time_frame>
    <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Safety Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
    <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Within the 4-days (Days 0-3) follow-up period following the booster vaccine administration</time_frame>
    <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Clinically Confirmed Acute Otitis Media (AOM) (C-AOM), in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks after Dose 3 to study end at Month 22-25</time_frame>
    <description>The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>CXR alveolar consolidation was defined as CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. CXR pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Any Bacterial Pathogen, in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes, in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes, in the Panama Subset.</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 6A, 18B, 19A and 23A. The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other Pneumococcal Serotypes, in the Panama Subset.</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>Other pneumococcal serotypes were defined for this outcome measures as non-Streptococcus pneumoniae vaccine and cross-reactive serotypes. The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Haemophilus Influenzae (H. Influenzae), in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Non-typeable Haemophilus Influenzae (H. Influenzae), in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The Panama Subset contained all subjects enrolled in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other AOM Pathogens, in the Panama Subset</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>Other pathogens assessed included among others Moraxella catarrhalis, Group A streptococci, and Staphyloccus aureus. The Panama Subset contained all subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP) With Positive Respiratory Viral Test (RVT)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>A CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal CXR With Positive Respiratory Viral Test (RVT)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>An &quot;abnormal CXR&quot; was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) With Positive Respiratory Viral Test (RVT).</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>An episode of S-CAP involved either any subject who was referred to have a chest X-ray (CXR) performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal Chest X-ray (CXR)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>An &quot;abnormal CXR&quot; was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP) With C Reactive Protein (CRP) &gt;= Cut-off, Regardless of Chest X-ray (CXR) Reading</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>A case of S-CAP involved either any subject who was referred to have a CXR performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI. CRP cut-off values applied for this outcome measure were 40 milligrams per liter (mg/L), 80 mg/L, and 120 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of CAP With Either Alveolar Consolidation/Pleural Effusion on Chest X-ray (CXR) (C-CAP) or With Non-alveolar Infiltrates (NAI-CAP) But With C Reactive Protein (CRP) &gt;= Cut-off.</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>CRP cut-off values applied for this outcome measure were 80 milligrams per liter (mg/L), and 120 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Vaccine-type Invasive Pneumococcal Disease (VT-IPD).</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>A VT-IPD was defined as a bacteriologically culture confirmed invasive pneumococcal disease case caused by any of the 10 pneumococcal Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of a Bacteriologically Confirmed Invasive Pneumococcal Disease (Bact.-Conf. ID).</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>A Bact.-conf. ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes as identified through positive culture. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Pneumococcal Invasive Disease (Pneumococcal ID)</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>A Pneumococcal ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Pneumococcal ID cases were identified through non-culture pneumococcal diagnostic tests with additional non-culture vaccine type serotyping. Tests used included rapid in-vitro diagnostic tests or Latex agglutination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Streptococcus (S. pn.) Cross-reactive Pneumococcal Serotypes.</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 19A, 6A and 9N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Pneumococcal Serotypes Other Than Streptococcus (S. pn.) Vaccine and Cross-reactive Serotypes.</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>The serotypes assessed for this outcome measure included among others the pneumococcal serotypes 12F, 16F, 24F, 38 and 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a First Episode Reported of Invasive Disease (ID) Due to Haemophilus Influenzae</measure>
    <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
    <description>No subject was reported with any case of ID due to Haemophilus influenzae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</measure>
    <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>The 10 pneumococcal S. pn. vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum.
The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</measure>
    <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>Any serotype belonging to the same serogroup as the Synflorix vaccine serotypes, but different from the vaccine serotypes, was considered for this analysis of carriage S. pn. cross-reactive serotypes. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Serotypes Identified in Nasopharyngeal Swabs Other Than the Synflorix Vaccine and Cross-reactive Serotypes, in the Carriage Subset</measure>
    <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With H. Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</measure>
    <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>Results included samples confirmed as positive for Haemophilus influenzae (H. influenzae) or non-typeable H. influenzae (NTHi) after differentiation from H. haemolyticus by polymerase chain reaction (PCR) assay. The Carriage Subset contained a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Acquisition of New Streptococcus Pneumoniae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</measure>
    <time_frame>At Months 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Acquisition of New Haemophilus Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset.</measure>
    <time_frame>At Months 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
    <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Antibiotic Prescription at Least Once During the Entire Study Period, in the Carriage Subset.</measure>
    <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
    <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed with the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pneumococcal Antibody Concentrations Against Cross-reactive Serotypes 6A and 19A Higher &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST</time_frame>
    <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST) .</time_frame>
    <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination,</time_frame>
    <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Opsonophagocytic Activity Against Pneumococcal Serotypes 6A and 19A in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 8, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
    <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Titers for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST).</time_frame>
    <description>A seropositive subject was a subject with titers for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 Post-BST and M9 POST-BST)</time_frame>
    <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset</measure>
    <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
    <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset.</measure>
    <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 Post-BST and M9 POST-BST</time_frame>
    <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23802</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine GSK1024850A</intervention_name>
    <description>Intramuscular injection, 4 doses</description>
    <arm_group_label>Synflorix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix</intervention_name>
    <description>Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group</description>
    <arm_group_label>Synflorix Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Hepatitis A vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Hepatitis B vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa</intervention_name>
    <description>Intramuscular injection,3 doses</description>
    <arm_group_label>Synflorix Group</arm_group_label>
    <other_name>DTPa-HBV-IPV/Hib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' DTPa-IPV/Hib vaccine</intervention_name>
    <description>Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group</description>
    <arm_group_label>Synflorix Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 6 and 16 weeks of age at the time of the
             first vaccination. Pre-term born infants can be included in the study starting from 8
             weeks of chronological age at the time of first vaccination and up to 16 weeks of
             chronological age

          -  Subjects should be living in the area covered by the surveillance system for community
             acquired pneumonia (CAP), invasive disease and acute otitis media (AOM) •Written
             informed consent obtained from the parent or guardian of the subject.

          -  Free of any known or suspected health problems (as established by medical history and
             clinical examination before entering into the study), that would contraindicate the
             initiation of routine immunizations outside a clinical trial context.

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or planned use during the study
             period.

          -  Use or planned use of any investigational or non-registered vaccine other than the
             study vaccine(s).

          -  Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae
             type b, hepatitis A and/or Streptococcus. pneumoniae . Locally recommended EPI
             vaccines to be given at birth are allowed, but should be administered at least one
             month before the first dose of the study vaccine .Other locally recommended vaccines
             are always allowed, even if concomitantly administered with the study vaccines.
             •Previous or planned vaccination with a registered pneumococcal vaccine such as
             Prevnar is not allowed. If Prevnar immunization needs to be initiated, due to the
             presence of a high risk disease for pneumococcal infections for which the Prevnar
             vaccine is made locally available, the subject can not be enrolled in the study and
             should be referred to the specific Prevnar immunization program.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment

          -  For Colombia: infants with low birth weight ( less than (&lt;) 2.500 grams)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>16 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Godoy Cruz</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guaymallen</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Heras</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luján de Cuyo</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villanueva</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albardón</city>
        <state>San Juan</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caucete</city>
        <state>San Juan</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fernandez</city>
        <state>Santiago Del Estero</state>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Banda</city>
        <state>Santiago Del Estero</state>
        <zip>4300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Banda</city>
        <zip>4300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maipu</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>5425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>san Martín</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <zip>4300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panama</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>Panama</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Borys D et al. Effect of 10- and 11-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccines (PHiD-CV and 11Pn-PD) on nasopharyngeal bacterial carriage. Abstract presented at the 8th Biennial International Symposium on Pneumococci &amp; Pneumococcal Diseases (ISPPD), Foz de Iguaçu, Brazil,11-15 March 2012 (Abstract 189).</citation>
  </reference>
  <reference>
    <citation>Sáez-Llorens X et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on nasopharyngeal bacterial carriage in Panamanian children. Abstract presented at the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011 (Abstract 854).</citation>
  </reference>
  <reference>
    <citation>Sáez-Llorens X et al. Design/setting of COMPAS: a Latin American trial evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). Abstract presented at the 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), The Hague, The Netherlands, 07-11 June, 2011.</citation>
  </reference>
  <reference>
    <citation>Sáez-Llorens X et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. Abstract presented at the 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR), Kuala Lumpur, 13-15 March 2013.</citation>
  </reference>
  <reference>
    <citation>Sáez-Llorens X et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) nasopharyngeal bacterial carriage in Panamanian children. Abstract presented at the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 16-19 November 2011.</citation>
  </reference>
  <reference>
    <citation>Saez-Llorens X et al. Impact of a pneumonia intervention in Latin America: Lessons from the COMPAS trial. Abstract presented at the 8th Biennial International Symposium on Pneumococci &amp; Pneumococcal Diseases (ISPPD). Foz de Iguaçu, Brazil, 11-15 March 2012.</citation>
  </reference>
  <reference>
    <citation>Tregnaghi et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against invasive pneumococcal disease in Latin America. Abstract presented at the 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR), Kuala Lumpur, 13-15 March 2013.</citation>
  </reference>
  <reference>
    <citation>Tregnaghi et al. Safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae porotein D conjugate vaccine and its effect on mortality: a randomized study.Abstract presented at the 31st Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID), Milan, Italy, 28 May-1 June 2013.</citation>
  </reference>
  <reference>
    <citation>Tregnaghi M et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-acquired pneumonia in Latin America: COMPAS results. Abstract presented at the 14th SLIPE. Punta Cana, Dominican Republic, 25-28 May 2011(Abstract 112).</citation>
  </reference>
  <reference>
    <citation>Tregnaghi M et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-acquired pneumonia in Latin America. Abstract presented at the 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), The Hague, The Netherlands, 07-11 June, 2011.</citation>
  </reference>
  <reference>
    <citation>Tregnaghi MW et al. Immunogenicity profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) in Latin American children enrolled in COMPAS. Abstract presented at the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011 (Abstract 430).</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <results_first_submitted>August 25, 2011</results_first_submitted>
  <results_first_submitted_qc>June 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2013</results_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Otitis media</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Community acquired pneumonia (CAP)</keyword>
  <keyword>Pneumococcal disease</keyword>
  <keyword>Booster vaccination</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Carriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109563</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Analysis on the primary outcome was performed when at least 535 first bacterial CAP episodes were reported from 2 weeks after vaccine Dose 3 (31 August 2010) with 23738 subjects (11875 and 11863 in Synflorix and Control groups) and analysis at study end was performed on 23597 subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Subjects received 3 doses of Engerix at 2,4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccine were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Outcome Analysis Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11875"/>
                <participants group_id="P2" count="11863"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="11875"/>
                <participants group_id="P2" count="11863"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No data on study completion and withdrawal were available at first analysis as the study was ongoing</participants>
                <participants group_id="P2" count="0">No data on study completion and withdrawal were available at first analysis as the study was ongoing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11875"/>
                <participants group_id="P2" count="11863"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other: study still ongoing</title>
              <participants_list>
                <participants group_id="P1" count="11875"/>
                <participants group_id="P2" count="11863"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study End Analysis Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11798"/>
                <participants group_id="P2" count="11799"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9302"/>
                <participants group_id="P2" count="9265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2496"/>
                <participants group_id="P2" count="2534"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1137"/>
                <participants group_id="P2" count="1167"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1264"/>
                <participants group_id="P2" count="1267"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other – Forbidden vaccination</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other – Subject without a legal guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other – Unconformity in team’s treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Subjects received 3 doses of Engerix at 2,4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccine were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11798"/>
            <count group_id="B2" value="11799"/>
            <count group_id="B3" value="23597"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline measures presented below correspond to those of the subjects whose data were exploited towards analysis of results at the end of the study</description>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" spread="1.93"/>
                    <measurement group_id="B2" value="9.2" spread="1.92"/>
                    <measurement group_id="B3" value="9.2" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline measures presented below correspond to those of the subjects whose data were exploited towards analysis of results at the end of the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5796"/>
                    <measurement group_id="B2" value="5767"/>
                    <measurement group_id="B3" value="11563"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6002"/>
                    <measurement group_id="B2" value="6032"/>
                    <measurement group_id="B3" value="12034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Baseline measures presented below correspond to those of the subjects whose data were exploited towards analysis of results at the end of the study</description>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6990"/>
                    <measurement group_id="B2" value="6991"/>
                    <measurement group_id="B3" value="13981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Columbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1206"/>
                    <measurement group_id="B2" value="1196"/>
                    <measurement group_id="B3" value="2402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3602"/>
                    <measurement group_id="B2" value="3612"/>
                    <measurement group_id="B3" value="7214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP)</title>
        <description>A B-CAP episode was defined as a radiologically confirmed community acquired pneumoniae (CAP) episode with either alveolar consolidation/pleural effusion on the chest X-ray (CXR) or with non-alveolar infiltrates but with C reactive protein (CRP) higher than or equal to (&gt;=) 40 milligrams per liter (mg/L). The results are presented for data lock point for the primary outcome analysis (31 August 2010), which was performed, as per protocol, when at least 535 first B-CAP episodes were reported from 2 weeks after the third vaccination dose.
After analysis on primary outcome was performed, re-monitoring activities revealed Informed Consent Form issues for some subjects. Therefore, a sensitivity analysis excluding 144 subjects was performed. This analysis confirmed the validity of the results for primary outcome.</description>
        <time_frame>Any time from 2 weeks after Dose 3 up to 31 August 2010</time_frame>
        <population>Analysis was performed on the Interim ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of 31 August 2010.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP)</title>
          <description>A B-CAP episode was defined as a radiologically confirmed community acquired pneumoniae (CAP) episode with either alveolar consolidation/pleural effusion on the chest X-ray (CXR) or with non-alveolar infiltrates but with C reactive protein (CRP) higher than or equal to (&gt;=) 40 milligrams per liter (mg/L). The results are presented for data lock point for the primary outcome analysis (31 August 2010), which was performed, as per protocol, when at least 535 first B-CAP episodes were reported from 2 weeks after the third vaccination dose.
After analysis on primary outcome was performed, re-monitoring activities revealed Informed Consent Form issues for some subjects. Therefore, a sensitivity analysis excluding 144 subjects was performed. This analysis confirmed the validity of the results for primary outcome.</description>
          <population>Analysis was performed on the Interim ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of 31 August 2010.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10295"/>
                <count group_id="O2" value="10201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
        <population>The analysis was performed on all vaccinated subjects whose data were exploited towards analysis of results at the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on all vaccinated subjects whose data were exploited towards analysis of results at the end of the study.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11798"/>
                <count group_id="O2" value="11799"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2534"/>
                    <measurement group_id="O2" value="2668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Event (AE), in the Panama Subset</title>
        <description>An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. The Panama Subset included all subjects from Panama.</description>
        <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Panama subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Event (AE), in the Panama Subset</title>
          <description>An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. The Panama Subset included all subjects from Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Panama subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3602"/>
                <count group_id="O2" value="3612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3530"/>
                    <measurement group_id="O2" value="3518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
        <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
          <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after vaccination with Infanrix Hexa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Infanrix Hexa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Infanrix Hexa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</title>
        <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period following the booster vaccine administration</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</title>
          <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Synflorix Group.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Synflorix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
        <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
          <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after vaccination with Engerix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Engerix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Engerix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset, for the Control Group</title>
        <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Safety Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period following the booster vaccine administration.</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset, for the Control Group</title>
          <description>Assessed symptoms were redness, swelling and pain. The Immunogenicity and Safety Tolerability Subset included 500 subjects coming from Argentina and Panama respectively. This outcome measure concerns solely subjects from the Control Group.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after vaccination with Havrix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness after vaccination with Havrix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Infanrix-IPV/Hib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling after vaccination with Havrix</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
        <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period across the 3 doses of the primary study vaccine administration</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms Post Primary Vaccination in the Immunogenicity and Tolerability Subset</title>
          <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (rectal temperature &gt;= 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</title>
        <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Within the 4-days (Days 0–3) follow-up period following the booster vaccine administration</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms Post Booster Vaccination in the Immunogenicity and Tolerability Subset</title>
          <description>Assessed symptoms were fever (defined as rectal temperature equal or higher than [&gt;=] 38 degrees Celsius [°C]). irritability/fussiness, drowsiness, and loss of appetite. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>The analysis was performed on all vaccinated subjects included in the Immunogenicity and Tolerability subset for the booster vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (rectal temperature &gt;= 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Clinically Confirmed Acute Otitis Media (AOM) (C-AOM), in the Panama Subset</title>
        <description>The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks after Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Clinically Confirmed Acute Otitis Media (AOM) (C-AOM), in the Panama Subset</title>
          <description>The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP)</title>
        <description>CXR alveolar consolidation was defined as CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. CXR pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP)</title>
          <description>CXR alveolar consolidation was defined as CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. CXR pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Any Bacterial Pathogen, in the Panama Subset</title>
        <description>The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Any Bacterial Pathogen, in the Panama Subset</title>
          <description>The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes, in the Panama Subset</title>
        <description>The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes, in the Panama Subset</title>
          <description>The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes, in the Panama Subset.</title>
        <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 6A, 18B, 19A and 23A. The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes, in the Panama Subset.</title>
          <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 6A, 18B, 19A and 23A. The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other Pneumococcal Serotypes, in the Panama Subset.</title>
        <description>Other pneumococcal serotypes were defined for this outcome measures as non-Streptococcus pneumoniae vaccine and cross-reactive serotypes. The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other Pneumococcal Serotypes, in the Panama Subset.</title>
          <description>Other pneumococcal serotypes were defined for this outcome measures as non-Streptococcus pneumoniae vaccine and cross-reactive serotypes. The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Haemophilus Influenzae (H. Influenzae), in the Panama Subset</title>
        <description>The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Haemophilus Influenzae (H. Influenzae), in the Panama Subset</title>
          <description>The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Non-typeable Haemophilus Influenzae (H. Influenzae), in the Panama Subset</title>
        <description>The Panama Subset contained all subjects enrolled in Panama</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Non-typeable Haemophilus Influenzae (H. Influenzae), in the Panama Subset</title>
          <description>The Panama Subset contained all subjects enrolled in Panama</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other AOM Pathogens, in the Panama Subset</title>
        <description>Other pathogens assessed included among others Moraxella catarrhalis, Group A streptococci, and Staphyloccus aureus. The Panama Subset contained all subjects enrolled in Panama.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacteriologically Confirmed Acute Otitis Media (AOM) (B-AOM) Due to Other AOM Pathogens, in the Panama Subset</title>
          <description>Other pathogens assessed included among others Moraxella catarrhalis, Group A streptococci, and Staphyloccus aureus. The Panama Subset contained all subjects enrolled in Panama.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3010"/>
                <count group_id="O2" value="2979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP) With Positive Respiratory Viral Test (RVT)</title>
        <description>A CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Alveolar Consolidation or Pleural Effusion on the Chest X-ray (CXR) (C-CAP) With Positive Respiratory Viral Test (RVT)</title>
          <description>A CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal CXR With Positive Respiratory Viral Test (RVT)</title>
        <description>An “abnormal CXR” was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal CXR With Positive Respiratory Viral Test (RVT)</title>
          <description>An “abnormal CXR” was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) With Positive Respiratory Viral Test (RVT).</title>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) With Positive Respiratory Viral Test (RVT).</title>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP)</title>
        <description>An episode of S-CAP involved either any subject who was referred to have a chest X-ray (CXR) performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP)</title>
          <description>An episode of S-CAP involved either any subject who was referred to have a chest X-ray (CXR) performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2108"/>
                    <measurement group_id="O2" value="2237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal Chest X-ray (CXR)</title>
        <description>An “abnormal CXR” was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Community Acquired Pneumoniae (CAP) With Any Abnormal Chest X-ray (CXR)</title>
          <description>An “abnormal CXR” was defined as a CXR with either consolidation, pleural effusion and/or abnormal pulmonary alveolar or non-alveolar infiltrates on the digital CXR image. CXR with consolidation was defined as a CXR with a dense, often homogeneous, confluent alveolar infiltrate that could encompass an entire lobe or segment, or a fluffy, mass-like, cloud-like density that erased heart and diaphragm borders (silhouette sign) and that often contained air bronchograms. Pleural effusion was defined as a fluid collecting in the pleural space around the lung, seen radiologically as a dense rim (the same density as the chest-wall muscles) interposed between the lung and the ribs.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681"/>
                    <measurement group_id="O2" value="764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP) With C Reactive Protein (CRP) &gt;= Cut-off, Regardless of Chest X-ray (CXR) Reading</title>
        <description>A case of S-CAP involved either any subject who was referred to have a CXR performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI. CRP cut-off values applied for this outcome measure were 40 milligrams per liter (mg/L), 80 mg/L, and 120 mg/L.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Suspected Community Acquired Pneumoniae (CAP) (S-CAP) With C Reactive Protein (CRP) &gt;= Cut-off, Regardless of Chest X-ray (CXR) Reading</title>
          <description>A case of S-CAP involved either any subject who was referred to have a CXR performed as part of the clinical assessment of a febrile syndrome or an acute respiratory infection (ARI), or a hospitalized child who had a CXR performed within 2 days prior to, or within the first 3 days after hospital admission, as part of the clinical assessment of a febrile syndrome or an ARI. CRP cut-off values applied for this outcome measure were 40 milligrams per liter (mg/L), 80 mg/L, and 120 mg/L.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S-CAP with CRP &gt;= 40 mg/L regardless of CXR exam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                    <measurement group_id="O2" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-CAP with CRP &gt;= 80 mg/L regardless of CXR exam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-CAP with CRP &gt;= 120 mg/L regardless of CXR exam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of CAP With Either Alveolar Consolidation/Pleural Effusion on Chest X-ray (CXR) (C-CAP) or With Non-alveolar Infiltrates (NAI-CAP) But With C Reactive Protein (CRP) &gt;= Cut-off.</title>
        <description>CRP cut-off values applied for this outcome measure were 80 milligrams per liter (mg/L), and 120 mg/L.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of CAP With Either Alveolar Consolidation/Pleural Effusion on Chest X-ray (CXR) (C-CAP) or With Non-alveolar Infiltrates (NAI-CAP) But With C Reactive Protein (CRP) &gt;= Cut-off.</title>
          <description>CRP cut-off values applied for this outcome measure were 80 milligrams per liter (mg/L), and 120 mg/L.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-CAP or NAI-CAP with CRP &gt;= 80 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-CAP or NAI-CAP with CRP &gt;= 120 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Vaccine-type Invasive Pneumococcal Disease (VT-IPD).</title>
        <description>A VT-IPD was defined as a bacteriologically culture confirmed invasive pneumococcal disease case caused by any of the 10 pneumococcal Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Vaccine-type Invasive Pneumococcal Disease (VT-IPD).</title>
          <description>A VT-IPD was defined as a bacteriologically culture confirmed invasive pneumococcal disease case caused by any of the 10 pneumococcal Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of a Bacteriologically Confirmed Invasive Pneumococcal Disease (Bact.-Conf. ID).</title>
        <description>A Bact.-conf. ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes as identified through positive culture. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of a Bacteriologically Confirmed Invasive Pneumococcal Disease (Bact.-Conf. ID).</title>
          <description>A Bact.-conf. ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes as identified through positive culture. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Pneumococcal Invasive Disease (Pneumococcal ID)</title>
        <description>A Pneumococcal ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Pneumococcal ID cases were identified through non-culture pneumococcal diagnostic tests with additional non-culture vaccine type serotyping. Tests used included rapid in-vitro diagnostic tests or Latex agglutination.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Pneumococcal Invasive Disease (Pneumococcal ID)</title>
          <description>A Pneumococcal ID was defined as a bacteriologically culture confirmed invasive pneumococcal disease (ID) cases due to any of the 10 Streptococcus pneumoniae vaccine serotypes. The 10 pneumococcal S. pneumoniae vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Pneumococcal ID cases were identified through non-culture pneumococcal diagnostic tests with additional non-culture vaccine type serotyping. Tests used included rapid in-vitro diagnostic tests or Latex agglutination.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Streptococcus (S. pn.) Cross-reactive Pneumococcal Serotypes.</title>
        <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 19A, 6A and 9N.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Streptococcus (S. pn.) Cross-reactive Pneumococcal Serotypes.</title>
          <description>The S. pn. cross-reactive serotypes assessed for this outcome measure were the serotypes 19A, 6A and 9N.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Pneumococcal Serotypes Other Than Streptococcus (S. pn.) Vaccine and Cross-reactive Serotypes.</title>
        <description>The serotypes assessed for this outcome measure included among others the pneumococcal serotypes 12F, 16F, 24F, 38 and 8.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a First Episode Reported of Invasive Pneumococcal Disease (IPD) Due to Pneumococcal Serotypes Other Than Streptococcus (S. pn.) Vaccine and Cross-reactive Serotypes.</title>
          <description>The serotypes assessed for this outcome measure included among others the pneumococcal serotypes 12F, 16F, 24F, 38 and 8.</description>
          <population>Analysis was performed on the Final ATP cohort for efficacy which included all evaluable vaccinated subjects who had received the 3-dose primary vaccination course, with available contact and efficacy data beyond Day 14 post study vaccine Dose 3, and whose parents/guardians consented to the use of the subject’s data as of study end.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10211"/>
                <count group_id="O2" value="10140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a First Episode Reported of Invasive Disease (ID) Due to Haemophilus Influenzae</title>
        <description>No subject was reported with any case of ID due to Haemophilus influenzae.</description>
        <time_frame>Any time from 2 weeks post primary vaccination Dose 3 to study end at Month 22-25</time_frame>
        <posting_date>12/2050</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
        <description>The 10 pneumococcal S. pn. vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum.
The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Vaccine Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
          <description>The 10 pneumococcal S. pn. vaccine serotypes assessed for this outcome measure were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum.
The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 5 (N=814; 814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10-13 (N=788; 784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=758; 762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720; 738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696; 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25 (N=627; 639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
        <description>Any serotype belonging to the same serogroup as the Synflorix vaccine serotypes, but different from the vaccine serotypes, was considered for this analysis of carriage S. pn. cross-reactive serotypes. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Cross-reactive Serotypes Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
          <description>Any serotype belonging to the same serogroup as the Synflorix vaccine serotypes, but different from the vaccine serotypes, was considered for this analysis of carriage S. pn. cross-reactive serotypes. S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 5 (N=814; 814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10-13 (N=788; 784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=758; 762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720; 738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696; 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25 (N=627; 639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Serotypes Identified in Nasopharyngeal Swabs Other Than the Synflorix Vaccine and Cross-reactive Serotypes, in the Carriage Subset</title>
        <description>S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Streptococcus Pneumoniae (S. pn.) Serotypes Identified in Nasopharyngeal Swabs Other Than the Synflorix Vaccine and Cross-reactive Serotypes, in the Carriage Subset</title>
          <description>S. pn. serotypes were identified using latex agglutination and by quellung reaction with omni serum. The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 5 (N=814; 814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10-13 (N=788; 784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=758; 762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720; 738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696; 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25 (N=627; 639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With H. Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</title>
        <description>Results included samples confirmed as positive for Haemophilus influenzae (H. influenzae) or non-typeable H. influenzae (NTHi) after differentiation from H. haemolyticus by polymerase chain reaction (PCR) assay. The Carriage Subset contained a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 5, 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With H. Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</title>
          <description>Results included samples confirmed as positive for Haemophilus influenzae (H. influenzae) or non-typeable H. influenzae (NTHi) after differentiation from H. haemolyticus by polymerase chain reaction (PCR) assay. The Carriage Subset contained a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 5 (N=824; 820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10-13 (N=788;785)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=757;762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720; 737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696; 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25 (N=628; 640)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Acquisition of New Streptococcus Pneumoniae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</title>
        <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Acquisition of New Streptococcus Pneumoniae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset</title>
          <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="788"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 10-13 (N=788;784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=758;762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720;738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696;690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25;N=627;639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Acquisition of New Haemophilus Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
        <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>At Months 10-13, 13-16, 14-17, 16-19 and 22-25</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Acquisition of New Haemophilus Influenzae Strains Identified in Nasopharyngeal Swabs, in the Carriage Subset.</title>
          <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="788"/>
                <count group_id="O2" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 10-13 (N=788;785)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13-16 (N=757;762)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14-17 (N=720;737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16-19 (N=696;690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22-25 (N=628;640)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Antibiotic Prescription at Least Once During the Entire Study Period, in the Carriage Subset.</title>
        <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
        <time_frame>Throughout the study (Month 0 to Month 22-25)</time_frame>
        <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Antibiotic Prescription at Least Once During the Entire Study Period, in the Carriage Subset.</title>
          <description>The Carriage Subset consisted in a subgroup of 2,000 subjects enrolled in Panama.</description>
          <population>The analysis was performed on all vaccinated subjects included in the carriage subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="966"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611"/>
                    <measurement group_id="O2" value="626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1 (N=334;312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="2.29" upper_limit="2.75"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4 (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" lower_limit="2.98" upper_limit="3.56"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5 (N=334;324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.86" upper_limit="4.57"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANITI-6B (N=334;322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.18" upper_limit="1.52"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="3.56" upper_limit="4.19"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" lower_limit="2.84" upper_limit="3.50"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14 (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" lower_limit="4.07" upper_limit="5.10"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.08" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" lower_limit="4.73" upper_limit="5.99"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F (N=334;327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="4.70" upper_limit="6.06"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.76" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A (N=334;321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.27" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A (N=334;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.25" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Vaccine Serotypes, in the Immunogenicity and Tolerability Subset.</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1, PRE (N=231;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.31" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M1 POST-BST (N=219;196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="3.15" upper_limit="4.07"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.56" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.42" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M1 POST-BST (N=217;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" lower_limit="5.81" upper_limit="7.38"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.77" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, PRE (N=231;209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.80" upper_limit="1.01"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.07" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M1 POST-BST (N=219;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" lower_limit="5.04" upper_limit="6.50"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.06" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.05" upper_limit="1.36"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.08" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.47" upper_limit="0.64"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M1 POST-BST (N=217;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="2.92" upper_limit="3.77"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.71" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.84" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M1 POST-BST (N=218;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" lower_limit="5.23" upper_limit="6.36"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.19" upper_limit="1.45"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, PRE (N=230;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="1.00" upper_limit="1.31"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M1 POST-BST (N=218;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" lower_limit="6.51" upper_limit="8.27"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.59" upper_limit="2.03"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.15" upper_limit="1.35"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.09" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M1 POST-BST (N=219;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" lower_limit="8.18" upper_limit="10.60"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.10" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="1.74" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.79" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M1 POST-BST (N=219;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.38" lower_limit="14.47" upper_limit="18.55"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="2.21" upper_limit="2.83"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, PRE (N=231;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="1.09" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M1 POST-BST (N=219;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" lower_limit="8.40" upper_limit="10.52"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M9 POST-BST (N=205;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" lower_limit="2.16" upper_limit="2.84"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.08" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, PRE (N=229;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.53" upper_limit="0.72"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" lower_limit="3.49" upper_limit="4.62"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M9 POST-BST (N=206;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.80" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was &gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.18" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M1 POST-BST (N=219;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.93" upper_limit="1.40"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.26" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.21" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.11" upper_limit="1.62"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.46" upper_limit="0.65"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.07" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed were the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1 (N=334;312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4 (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5 (N=334;324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANITI-6B (N=334;322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14 (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F (N=334;327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A (N=334;321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A (N=334;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed with the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Vaccine Serotypes &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). Serotypes assessed with the pneumococcal vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1, PRE (N=231;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M1 POST-BST (N=219;196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M1 POST-BST (N=217;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, PRE (N=231;209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M1 POST-BST (N=219;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M1 POST-BST (N=217;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M1 POST-BST (N=218;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, PRE (N=230;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M1 POST-BST (N=218;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M1 POST-BST (N=219;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M1 POST-BST (N=219;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, PRE (N=231;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M1 POST-BST (N=219;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M9 POST-BST (N=205;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, PRE (N=229;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M9 POST-BST (N=206;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Cross-reactive Serotypes 6A and 19A Higher &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Cross-reactive Serotypes 6A and 19A Higher &gt;= 0.20 Micrograms Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M1 POST-BST (N=219;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1 (N=334;312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4 (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5 (N=334;324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANITI-6B (N=334;322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14 (N=334;330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C (N=334;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F (N=334;327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F (N=334;331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A (N=334;321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A (N=334;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 0.05 Microgram Per Milliliter (µg/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with antibody concentrations against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1, PRE (N=231;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M1 POST-BST (N=219;196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M1 POST-BST (N=217;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, PRE (N=231;209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M1 POST-BST (N=219;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M1 POST-BST (N=217;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M1 POST-BST (N=218;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, PRE (N=230;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M1 POST-BST (N=218;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M1 POST-BST (N=219;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, PRE (N=231;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M1 POST-BST (N=219;203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, PRE (N=231;206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M1 POST-BST (N=219;198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F, M9 POST-BST (N=205;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, PRE (N=229;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F, M9 POST-BST (N=206;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST) .</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Pneumococcal Antibody Concentrations Against Serotypes 6A and 19A &gt;= 0.05 µg/mL, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with antibody concentrations against cross-reactive pneumococcal serotypes 6A and 19A&gt;= 0.05 µg/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A, PRE (N=231;214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M1 POST-BST (N=219;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A, M9 POST-BST (N=206;183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, PRE (N=229;212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M1 POST-BST (N=218;201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A, M9 POST-BST (N=206;181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</title>
        <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination,</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</title>
          <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1 (N=306;305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" lower_limit="116.8" upper_limit="166.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.5" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4 (N=310;299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.7" lower_limit="686.5" upper_limit="867.6"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.5" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5 (N=313;314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.8" lower_limit="196.0" upper_limit="257.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B (N=315;309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689.7" lower_limit="553.2" upper_limit="859.7"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F (N=302;266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4656.7" lower_limit="4175.6" upper_limit="5193.3"/>
                    <measurement group_id="O2" value="110.4" lower_limit="78.8" upper_limit="154.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V (N=312;302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1690.4" lower_limit="1489.4" upper_limit="1918.7"/>
                    <measurement group_id="O2" value="14.6" lower_limit="11.6" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14 (N=308;273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="908.5" lower_limit="795.2" upper_limit="1038.1"/>
                    <measurement group_id="O2" value="16.5" lower_limit="12.9" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C (N=308;317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.9" lower_limit="259.4" upper_limit="372.6"/>
                    <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F (N=304;314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383.0" lower_limit="308.5" upper_limit="475.5"/>
                    <measurement group_id="O2" value="4.7" lower_limit="4.3" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F (N=317;282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2167.4" lower_limit="1863.4" upper_limit="2521.1"/>
                    <measurement group_id="O2" value="14.5" lower_limit="11.0" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
        <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Safety Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A, in the Immunogenicity and Tolerability Subset</title>
          <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Safety Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-6A (N=297;305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.9" lower_limit="121.8" upper_limit="202.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.5" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A (N=302;309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="14.5" upper_limit="22.9"/>
                    <measurement group_id="O2" value="4.1" lower_limit="4.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</title>
        <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in the Immunogenicity and Tolerability Subset</title>
          <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1, PRE (N=221;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="7.4" upper_limit="10.9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.2" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, M1 POST-BST (N=209;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.5" lower_limit="281.8" upper_limit="453.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, M9 POST-BST (N=196;176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="26.6" upper_limit="44.7"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.2" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, PRE (N=208;193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="21.2" upper_limit="40.2"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.4" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M1 POST-BST (N=207;193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2853.5" lower_limit="2365.5" upper_limit="3442.1"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.3" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M9 POST-BST (N=192;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.6" lower_limit="115.3" upper_limit="237.9"/>
                    <measurement group_id="O2" value="8.1" lower_limit="6.1" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, PRE (N=205;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="15.4" upper_limit="22.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="4.1" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M1 POST-BST (N=196;187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.1" lower_limit="252.0" upper_limit="371.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M9 POST-BST (N=192;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" lower_limit="35.5" upper_limit="54.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, PRE (N=209;197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="70.1" upper_limit="130.1"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.0" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M1 POST-BST (N=203;190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1123.4" lower_limit="939.2" upper_limit="1343.9"/>
                    <measurement group_id="O2" value="7.1" lower_limit="5.6" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M9 POST-BST (N=178;165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" lower_limit="92.7" upper_limit="179.2"/>
                    <measurement group_id="O2" value="11.4" lower_limit="8.3" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, PRE (N=217;202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522.8" lower_limit="1338.5" upper_limit="1732.6"/>
                    <measurement group_id="O2" value="979.5" lower_limit="821.2" upper_limit="1168.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M1 POST-BST (N=205;196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4336.3" lower_limit="3607.9" upper_limit="5211.8"/>
                    <measurement group_id="O2" value="746.4" lower_limit="590.7" upper_limit="943.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M9 POST-BST (N=192;172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2598.0" lower_limit="2232.0" upper_limit="3024.1"/>
                    <measurement group_id="O2" value="1214.3" lower_limit="1011.4" upper_limit="1458.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, PRE (N=213;188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709.4" lower_limit="601.7" upper_limit="836.3"/>
                    <measurement group_id="O2" value="233.7" lower_limit="175.3" upper_limit="311.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M1 POST-BST (N=200;189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3763.0" lower_limit="3317.5" upper_limit="4268.3"/>
                    <measurement group_id="O2" value="250.9" lower_limit="186.1" upper_limit="338.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M9 POST-BST (N=194;168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1320.3" lower_limit="1153.1" upper_limit="1511.7"/>
                    <measurement group_id="O2" value="337.4" lower_limit="252.4" upper_limit="451.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, PRE (N=205;192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.2" lower_limit="89.7" upper_limit="163.8"/>
                    <measurement group_id="O2" value="27.0" lower_limit="18.9" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M1 POST-BST (N=209;188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2659.6" lower_limit="2266.2" upper_limit="3121.3"/>
                    <measurement group_id="O2" value="21.7" lower_limit="15.0" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M9 POST-BST (N=185;159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.6" lower_limit="242.7" upper_limit="450.5"/>
                    <measurement group_id="O2" value="27.6" lower_limit="18.3" upper_limit="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, PRE (N=204;191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="11.5" upper_limit="19.6"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M1 POST-BST (N=188;187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2426.0" lower_limit="2041.8" upper_limit="2882.5"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.4" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M9 POST-BST (N=170;164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722.0" lower_limit="553.6" upper_limit="941.6"/>
                    <measurement group_id="O2" value="5.3" lower_limit="4.4" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, PRE (N=218;205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="19.6" upper_limit="30.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.4" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M1 POST-BST (N=199;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657.5" lower_limit="497.4" upper_limit="869.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.4" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M9 POST-BST (N=194;170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.0" lower_limit="90.6" upper_limit="153.7"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.3" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, PRE (N=215;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.3" lower_limit="494.3" upper_limit="933.6"/>
                    <measurement group_id="O2" value="76.9" lower_limit="49.0" upper_limit="120.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M1 POST-BST (N=206;190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4278.3" lower_limit="3609.3" upper_limit="5071.3"/>
                    <measurement group_id="O2" value="99.7" lower_limit="62.7" upper_limit="158.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M9 POST-BST (N=187;167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999.6" lower_limit="711.8" upper_limit="1403.9"/>
                    <measurement group_id="O2" value="109.4" lower_limit="65.7" upper_limit="182.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Opsonophagocytic Activity Against Pneumococcal Serotypes 6A and 19A in the Immunogenicity and Tolerability Subset</title>
        <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Opsonophagocytic Activity Against Pneumococcal Serotypes 6A and 19A in the Immunogenicity and Tolerability Subset</title>
          <description>The cut-off of the assay was &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-6A, PRE (N=189;194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="31.0" upper_limit="62.0"/>
                    <measurement group_id="O2" value="7.1" lower_limit="5.7" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M1 POST BST (N=185;185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.2" lower_limit="198.7" upper_limit="386.7"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.0" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M9 POST-BST (N=175;156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" lower_limit="44.3" upper_limit="92.0"/>
                    <measurement group_id="O2" value="17.2" lower_limit="12.1" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, PRE (N=217;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.3" upper_limit="7.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.4" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M1 POST-BST (N=200;197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.8" lower_limit="97.5" upper_limit="180.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M9 POST-BST (N=187;171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="19.5" upper_limit="35.1"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.3" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 8, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F =&gt; 8, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1 (N=306;305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4 (N=310;299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5 (N=313;314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B (N=315;309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F (N=302;266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V (N=312;302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14 (N=308;273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C (N=308;317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F (N=304;314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F (N=317;282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against cross-reactive pneumococcal serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-6A (N=297;305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A (N=302;309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with titers for opsonophagocytic activity against vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1, PRE (N=221;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, M1 POST-BST (N=209;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, M9 POST-BST (N=196;176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, PRE (N=208;193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M1 POST-BST (N=207;193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, M9 POST-BST (N=192;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, PRE (N=205;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M1 POST-BST (N=196;187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, M9 POST-BST (N=192;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, PRE (N=209;197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M1 POST-BST (N=203;190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, M9 POST-BST (N=178;165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, PRE (N=217;202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M1 POST-BST (N=205;196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, M9 POST-BST (N=192;172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, PRE (N=213;188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M1 POST-BST (N=200;189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, M9 POST-BST (N=194;168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, PRE (N=205;192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M1 POST-BST (N=209;188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, M9 POST-BST (N=185;159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, PRE (N=204;191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M1 POST-BST (N=188;187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, M9 POST-BST (N=170;164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, PRE (N=218;205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M1 POST-BST (N=199;200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, M9 POST-BST (N=194;170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, PRE (N=215;199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M1 POST-BST (N=206;190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, M9 POST-BST (N=187;167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was a subject with titers for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 POST-BST and M9 POST-BST).</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Titers for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A &gt;= 8, in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was a subject with titers for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A &gt;= 8. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-6A, PRE (N=189;194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M1 POST BST (N=185;185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, M9 POST-BST (N=175;156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, PRE (N=217;204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M1 POST-BST (N=200;197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, M9 POST-BST (N=187;171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</title>
        <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</title>
          <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2455.2" lower_limit="2248.3" upper_limit="2681.1"/>
                    <measurement group_id="O2" value="101.2" lower_limit="91.3" upper_limit="112.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</title>
        <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 Post-BST and M9 POST-BST)</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Protein D (ANTI-PD), in the Immunogenicity and Tolerability Subset</title>
          <description>ANTI-PD concentrations are expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-PD, PRE (N=230;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638.6" lower_limit="556.2" upper_limit="733.2"/>
                    <measurement group_id="O2" value="103.1" lower_limit="90.5" upper_limit="117.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-PD, M1 POST BST (N=218;195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2787.0" lower_limit="2435.9" upper_limit="3188.7"/>
                    <measurement group_id="O2" value="92.4" lower_limit="82.6" upper_limit="103.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-PD, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="824.1" lower_limit="704.2" upper_limit="964.4"/>
                    <measurement group_id="O2" value="94.5" lower_limit="84.4" upper_limit="105.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset</title>
        <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>At Month 5, one month after the third dose of primary vaccination</time_frame>
        <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset</title>
          <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Primary According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Tolerability Subset (500 subjects in Argentina, 500 in Panama) with post primary vaccination assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset.</title>
        <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
        <time_frame>Before the administration of booster vaccination (PRE), and 1 month and 9 months post booster vaccination (M1 Post-BST and M9 POST-BST</time_frame>
        <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Safety Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-protein D (ANTI-PD) Antibody Concentrations &gt;= 100 Enzyme-linked Immunosorbent Assay Units Per Milliliter ( EL.U/mL), in the Immunogenicity and Tolerability Subset.</title>
          <description>A seropositive subject was defined as a subject with ANTI-PD antibody concentrations &gt;= 100 EL.U/mL. The Immunogenicity and Tolerability Subset included 500 subjects coming from Argentina and Panama respectively.</description>
          <population>Analyses were performed on the Booster According-to-Protocol immunogenicity cohort, including all evaluable subjects in the Immunogenicity and Safety Subset (500 subjects in Argentina, 500 in Panama) with post booster assay results against at least 1 study vaccine antigen component and concerning immunogenicity outcomes available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-PD, PRE (N=230;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-PD, M1 POST BST (N=218;195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-PD, M9 POST-BST (N=206;182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and unsolicited AEs: Throughout the study (Months 0 to 22-25). Solicited symptoms: 4-day (Days 0–3) follow-up period across the 3 doses of primary study vaccine course/ 4-day (Days 0–3) follow-up period post booster vaccination</time_frame>
      <desc>Reports for SAEs were collected from all subjects from the Total Vaccinated cohort (TVC). Reports for unsolicited AEs and for solicited symptoms were collected from subjects from the TVC from the Panama Subset and from the Immunogenicity and Tolerability Subset, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2534" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2668" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Leukaemoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Congenital absence of bile ducts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Congenital oral malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Congenital syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningomyelocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Porencephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Retinoblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Spinal muscular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Thalassaemia sickle cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperadrenalism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Electrocution</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Selective iga immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Abscess of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="473" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="518" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cat scratch disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Colostomy infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Conjunctivitis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="553" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="497" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hantaviral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningitis meningococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="478" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="557" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Staphylococcal scalded skin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Thyroglossal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Electrical burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Eye burns</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Gingival injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Herbal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Vulvovaginal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acid base balance abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Aspiration bronchial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cow’s milk intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="463" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="438" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Connective tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hepatoblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Nephroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Retinoblastoma bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cns ventriculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Myoclonic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Post-traumatic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Binge eating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Psychomotor retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Infantile asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute haemorrhagic oedema of infancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Cutaneous loxoscelism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haemorrhagic urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Rash scarlatiniform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Skin oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Physical abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Therapeutic hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary fragility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Kawasaki’s disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11799"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11798"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11799"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3530" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="3518" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1411" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="1378" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="598" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="575" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1905" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="1794" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="520" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="506" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="384" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2272" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="1916" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="458" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix Hexa. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix Hexa. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix-IPV/Hib. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Engerix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix Hexa. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix-IPV/Hib. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Engerix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Infanrix-IPV/Hib.</description>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Havrix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Infanrix-IPV/Hib.</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Havrix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Synflorix. Collect of results did not apply to subjects in the Control Group.</description>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling†</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Infanrix-IPV/Hib.</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination with Havrix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vacAE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccinationcination</description>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Fever (rectal temperature &gt;= 38.0°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination</description>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination</description>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination</description>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination</description>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Fever (rectal temperature &gt;= 38.0°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination</description>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination</description>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post booster vaccination</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Infanrix-IPV/Hib. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>AE collected in subjects in the Immunogenicity and Tolerability Subset post primary vaccination with Engerix. Collect of results did not apply to subjects in the Synflorix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="328" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3338" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="3326" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1310" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="1281" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1119" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="1123" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="950" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="958" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="714" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="738" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="672" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="682" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="542" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="516" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="497" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="474" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="410" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="350" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="368" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="454" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="406" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="556" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="545" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Overweight</sub_title>
                <counts group_id="E1" subjects_affected="416" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="422" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="596" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="582" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="499" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="510" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="288" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="313" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="322" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="468" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="464" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="316" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="296" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="220" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="3612"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="3602"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="3612"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

